Risk of hypomagnesaemia with proton pump inhibitors

被引:0
作者
不详
机构
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A recent international safety advisory has warned of a potential association between prolonged use of proton pump inhibitors (PPIs) and serious hypomagnesaemia-related adverse events such as tetany, seizures, delirium and cardiac arrhythmias. While this occurs rarely, prescribers should be vigilant to PPI-associated hypomagnesaemia. Patients presenting with hypomagnesaemia may require PPI discontinuation.
引用
收藏
页码:81 / 81
页数:1
相关论文
共 5 条
  • [1] [Anonymous], FDA DRUG SAF COMM LO
  • [2] Proton pump inhibitors and severe hypomagnesaemia
    Cundy, Tim
    Mackay, Jonathan
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2011, 27 (02) : 180 - 185
  • [3] Proton-pump inhibitors and hypomagnesemic hypoparathyroidism
    Epstein, Martin
    McGrath, Shaun
    Law, Florence
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (17) : 1834 - 1836
  • [4] Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series
    Mackay, J. D.
    Bladon, P. T.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (06) : 387 - 395
  • [5] Magnesium: the forgotten electrolyte
    Wu, Joyce
    Carter, Andrew
    [J]. AUSTRALIAN PRESCRIBER, 2007, 30 (04) : 102 - 105